Enterome SA, a Paris, France-based clinical-stage biopharmaceutical company leveraging its knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, raised €46.3m ($52.6m) in funding.
As part of this financing, Enterome has closed a Series E round with new investors including SymBiosis, LLC, a microbiome-focused investment vehicle, and Takeda Pharmaceutical Company Limited. Existing Enterome investors – Seventure, Health for Life Capital, Principia, Omnes Capital and Nestlé Health Science – also participated in the round. In addition, Enterome has made a first drawdown from a loan facility provided by the European Investment Bank (EIB) under a 2018 agreement.
The company intends to use the funds to progress the clinical development of its therapeutic pipeline, including the first clinical trials of EO2401, a novel ‘OncoMimic’ cancer immunotherapy and support its global partner Takeda Pharma to deliver proof-of-concept clinical data with EB8018 (sibofimloc/TAK-018), an oral FimH blocker for the treatment of Crohn’s disease.
Led by Pierre Belichard, CEO, Enterome is a world leader in the discovery and development of novel pharmaceuticals based on its understanding of the interaction between the gut microbiome and the immune system (the ‘microbiome-immunoinflammation axis’). The company is leveraging this expertise to develop a pipeline of clinical and pre-clinical candidates (small molecules, proteins and peptides) with a focus on cancer, autoimmune, inflammatory and metabolic diseases.
Drug candidates are:
immunotherapies against cancers (EO2401, EO2463). EO2401 is expected to enter Phase 1/2 clinical trials in patients with glioblastoma and in patients with adrenal malignancies, respectively, during mid-2020. EO2463, is being prepared as a clinical candidate for B-cell malignancies.
EndoMimics, a new generation of biologics for inflammatory diseases (EM101), Type 2 diabetes and inflammatory bowel disease.
Enterome’s most advanced drug candidate is EB8018 (also referred to as sibofimloc/TAK-018), which selectively blocks the virulence factor FimH, is advancing through clinical trials in Crohn’s disease. EB8018 has been partnered with Takeda globally, with the company retaining a significant profit share in the US. Enterome also has operations in Boston (US).